Claims for Patent: 8,754,106

Summary for Patent: 8,754,106

Title:	Macrocyclic inhibitors of hepatitis C virus
Abstract:	Inhibitors of HCV replication of formula (I) ##STR00001## and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond; X is N, CH and where X bears a double bond it is C; R.sup.1 is --OR.sup.7, --NH--SO.sub.2R.sup.8; R.sup.2 is hydrogen, and where X is C or CH, R.sup.2 may also be C.sub.1-6alkyl; R.sup.3 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxyC.sub.1-6alkyl, C.sub.3-7cycloalkyl; R.sup.4 is aryl or Het; n is 3, 4, 5, or 6; R.sup.5 is halo, C.sub.1-6alkyl, hydroxy, C.sub.1-6alkoxy, phenyl, or Het; R.sup.6 is C.sub.1-6alkoxy, or dimethylamino; R.sup.7 is hydrogen; aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; R.sup.8 is aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; aryl is phenyl optionally substituted with one, two or three substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, and being optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.
Inventor(s):	Simmen; Kenneth Alan (Tervuren, BE), De Kock; Herman Augustinus (Arendock, BE), Raboisson; Pierre Jean-Marie Bernard (Sterrebeek, BE), Hu; Lili (Mechelen, BE), Tahri; Abdellah (Anderlecht, BE), Surleraux; Dominique Louis Nestor Ghislain (Braine-le-chateau, BE), Nilsson; Karl Magnus (Goteborg, SE), Samuelsson; Bengt Bertil (Skarholmen, SE), Rosenquist; Asa Annica Kristina (Huddinge, SE), Ivanov; Vladimir (Moscow, RU), Pelcman; Mikael (Alvsjo, SE), Belfrage; Anna Karin Gertrud Linea (Uppsala, SE), Johansson; Per-Ola Mikael (Huddinge, SE), Vendeville; Sandrine Marie Helene (Etterbeek, BE)
Assignee:	Janssen R&D Ireland (Little Island, Country Cork, IE) Medivir AB (Huddinge, SE)
Application Number:	13/832,166
Patent Claims:	1. A combination comprising: (a) a compound having the formula ##STR00194## an N-oxide, salt, or stereoisomer thereof, wherein each dashed line (represented by - - - - -) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R.sup.1 is --OR.sup.7, --NH--SO.sub.2R.sup.8; R.sup.2 is hydrogen, and where X is C or CH, R.sup.2 may also be C.sub.1-6alkyl; R.sup.3 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxyC.sub.1-6alkyl, C.sub.3-7cycloalkyl; R.sup.4 is aryl or Het; n is 3, 4, 5, or 6; R.sup.5 represents halo, C.sub.1-6alkyl, hydroxy, C.sub.1-6alkoxy, polyhaloC.sub.1-6alkyl, phenyl, or Het; R.sup.6 represents C.sub.1-6alkoxy, or dimethylamino; R.sup.7 is hydrogen; aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; R.sup.8 is aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; aryl as a group or part of a group is phenyl optionally substituted with one, two or three substituents selected from halo, hydroxy, nitro, cyano, carboxyl, C.sub.1-6alkyl, C.sub.1-6alkoxy, C.sub.1-6alkoxyC.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, amino, mono- or di-C.sub.1-6alkylamino, azido, mercapto, polyhaloC.sub.1-6alkyl, polyhaloC.sub.1-6alkoxy, C.sub.3-7cycloalkyl, pyrrolidinyl, piperidinyl, piperazinyl, 4-C.sub.1-6alkylpiperazinyl, 4-C.sub.1-6alkylcarbonylpiperazinyl, and morpholinyl; wherein the morpholinyl and piperidinyl groups may be optionally substituted with one or with two C.sub.1-6alkyl radicals; Het as a group or part of a group is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally condensed with a benzene ring; and wherein said Het as a whole is optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, hydroxy, nitro, cyano, carboxyl, C.sub.1-6alkyl, C.sub.1-6alkoxy, C.sub.1-6alkoxyC.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, amino, mono- or di-C.sub.1-6alkylamino, azido, mercapto, polyhaloC.sub.1-6alkyl, polyhaloC.sub.1-6alkoxy, C.sub.3-7cycloalkyl, pyrrolidinyl, piperidinyl, piperazinyl, 4-C.sub.1-6alkylpiperazinyl, 4-C.sub.1-6alkylcarbonylpiperazinyl, and morpholinyl; wherein the morpholinyl and piperidinyl groups may be optionally substituted with one or with two C.sub.1-6alkyl radicals; and (b) another anti-HCV compound. 2. The combination according to claim 1, wherein the compound of formula (I) has the formula (I-c), (I-d), or (I-e): ##STR00195## 3. The combination according to claim 1 wherein the compound of formula (I) has the formula (I-b): ##STR00196## 4. The combination according to claim 3 wherein R.sup.2 is hydrogen; and a double bond is present between carbon atoms 7 and 8. 5. The combination according to claim 1, wherein R.sup.4 is selected from the group consisting of phenyl, pyridin-4-yl, ##STR00197## wherein R.sup.4a is, each independently, hydrogen, halo, C.sub.1-6alkyl, amino, or mono- or di-C.sub.1-6alkylamino. 6. The combination according to claim 1, wherein R.sup.4 is a radical ##STR00198## wherein, where possible, a nitrogen may bear an R.sup.4a substituent or a link to the remainder of the molecule; each R.sup.4a in any of the R.sup.4 substituents may be selected from those mentioned as possible substituents on Het, as specified in claim 1. 7. The combination according to claim 1, wherein R.sup.4 is: ##STR00199## wherein each R.sup.4a is hydrogen, halo, C.sub.1-6alkyl, amino, or mono- or di-C.sub.1-6alkylamino, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, or 4-C.sub.1-6alkylpiperazinyl; and wherein the morpholinyl and piperidinyl groups may optionally be substituted with one or two C.sub.1-6alkyl radicals. 8. The combination according to claim 7, wherein in radicals (q-1), (q-2), (q-3), or (q-4) each R.sup.4a is independently, hydrogen, halo, C.sub.1-6alkyl, amino, or mono- or di-C.sub.1-6alkylamino. 9. The combination according to claim 1, wherein R.sup.5 is methyl, ethyl, isopropyl, tert-butyl, fluoro, chloro, or bromo. 10. The combination according to claim 1, wherein (a) R.sup.1 is --OR.sup.7, wherein R.sup.7 is C.sub.1-6alkyl or hydrogen; (b) R.sup.1 is --NHS(.dbd.O).sub.2R.sup.8, wherein R.sup.8 is methyl, cyclopropyl, or phenyl; or R.sup.1 is --NHS(.dbd.O).sub.2R.sup.8, wherein R.sup.8 is cyclopropyl substituted with methyl. 11. The combination according to claim 10, wherein R.sup.1 is --NHS(.dbd.O).sub.2R.sup.8, wherein R.sup.8 is methyl, cyclopropyl, or phenyl. 12. The combination according to claim 1, wherein n is 4 or 5. 13. The combination according to claim 12, wherein n is 4. 14. The combination according to claim 1, wherein R.sup.3 is hydrogen or C.sub.1-6alkyl. 15. The combination according to claim 14 wherein R.sup.3 is hydrogen or methyl. 16. The combination according to claim 1, wherein R.sup.6 is methoxy. 17. The combination according to claim 1 wherein the compound of formula (I) is: ##STR00200## 18. The combination according to claim 1 wherein the compound of formula (I) is: ##STR00201## 19. The combination according to claim 1 wherein the compound of formula (I) is: ##STR00202## 20. The combination according to claim 1 other than an N-oxide, or salt. 21. The combination according to claim 1 other than an N-oxide. 22. The combination as claimed in claim 1, wherein the other anti-HCV compound is an HCV polymerase inhibitor, an HCV protease inhibitor, an inhibitor of another target in the HCV life cycle, an immunomodulatory agent, an antiviral agent, or combinations thereof. 23. The combination as claimed in claim 22, wherein the other anti-HCV compound is an HCV polymerase inhibitor. 24. The combination as claimed in claim 22, for simultaneous, separate, or sequential use in the treatment of HCV infections. 25. The combination as claimed in claim 23, for simultaneous, separate, or sequential use in the treatment of HCV infections. 26. A method of inhibiting HCV replication comprising administering to a patient in need thereof, a compound of formula (I) ##STR00203## an N-oxide, salt, or stereoisomer thereof, wherein each dashed line (represented by - - - - -) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R.sup.1 is --OR.sup.7, --NH--SO.sub.2R.sup.8; R.sup.2 is hydrogen, and where X is C or CH, R.sup.2 may also be C.sub.1-6alkyl; R.sup.3 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxyC.sub.1-6alkyl, C.sub.3-7cycloalkyl; R.sup.4 is aryl or Het; n is 3, 4, 5, or 6; R.sup.5 represents halo, C.sub.1-6alkyl, hydroxy, C.sub.1-6alkoxy, polyhaloC.sub.1-6alkyl, phenyl, or Het; R.sup.6 represents C.sub.1-6alkoxy, or dimethylamino; R.sup.7 is hydrogen; aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; R.sup.8 is aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; aryl as a group or part of a group is phenyl optionally substituted with one, two or three substituents selected from halo, hydroxy, nitro, cyano, carboxyl, C.sub.1-6alkyl, C.sub.1-6alkoxy, C.sub.1-6alkoxyC.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, amino, mono- or di-C.sub.1-6alkylamino, azido, mercapto, polyhaloC.sub.1-6alkyl, polyhaloC.sub.1-6alkoxy, C.sub.3-7cycloalkyl, pyrrolidinyl, piperidinyl, piperazinyl, 4-C.sub.i-6alkylpiperazinyl, 4-C.sub.1-6alkylcarbonylpiperazinyl, and morpholinyl; wherein the morpholinyl and piperidinyl groups may be optionally substituted with one or with two C.sub.1-6alkyl radicals; Het as a group or part of a group is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally condensed with a benzene ring; and wherein said Het as a whole is optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, hydroxy, nitro, cyano, carboxyl, C.sub.1-6alkyl, C.sub.1-6alkoxy, C.sub.1-6alkoxyC.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, amino, mono- or di-C.sub.1-6alkylamino, azido, mercapto, polyhaloC.sub.1-6alkyl, polyhaloC.sub.1-6alkoxy, C.sub.3-7cycloalkyl, pyrrolidinyl, piperidinyl, piperazinyl, 4-C.sub.1-6alkylpiperazinyl, 4-C.sub.1-6alkylcarbonylpiperazinyl, and morpholinyl; wherein the morpholinyl and piperidinyl groups may be optionally substituted with one or with two C.sub.1-6alkyl radicals; in combination with another compound. 27. The method as claimed in claim 26, wherein the other compound is another anti-HCV compound. 28. The method as claimed in claim 27, wherein the other anti-HCV compound is an HCV polymerase inhibitor, and HCV protese inhibitor, an inhibitor of another target in the HCV life cycle, an immunomodulatory agent, an antiviral agent, or combinations thereof. 29. The method as claimed in claim 27, wherein the other anti-HCV compound is an HCV polymerase inhibitor. 30. The method as claimed in claim 28, wherein the combination therapy is for simultaneous, separate, or sequential use in the treatment of HCV infections. 31. The method as claimed in claim 28, wherein the combination therapy is for simultaneous, separate, or sequential use in the treatment of HCV infections. 32. A pharmaceutical composition comprising a carrier, and as active ingredient an anti-virally effective amount of a combination comprising: (a) a compound having the formula ##STR00204## an N-oxide, salt, or stereoisomer thereof, wherein each dashed line (represented by - - - - -) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R.sup.1 is --OR.sup.7, --NH--SO.sub.2R.sup.8; R.sup.2 is hydrogen, and where X is C or CH, R.sup.2 may also be C.sub.1-6alkyl; R.sup.3 is hydrogen, C.sub.1-6alkyl, C.sub.1-6alkoxyC.sub.1-6alkyl, C.sub.3-7cycloalkyl; R.sup.4 is aryl or Het; n is 3, 4, 5, or 6; R.sup.5 represents halo, C.sub.1-6alkyl, hydroxy, C.sub.1-6alkoxy, polyhaloC.sub.1-6alkyl, phenyl, or Het; R.sup.6 represents C.sub.1-6alkoxy, or dimethylamino; R.sup.7 is hydrogen; aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; R.sup.8 is aryl; Het; C.sub.3-7cycloalkyl optionally substituted with C.sub.1-6alkyl; or C.sub.1-6alkyl optionally substituted with C.sub.3-7cycloalkyl, aryl or with Het; aryl as a group or part of a group is phenyl optionally substituted with one, two or three substituents selected from halo, hydroxy, nitro, cyano, carboxyl, C.sub.1-6alkyl, C.sub.1-6alkoxy, C.sub.1-6alkoxyC.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, amino, mono- or di-C.sub.1-6alkylamino, azido, mercapto, polyhaloC.sub.1-6alkyl, polyhaloC.sub.1-6alkoxy, C.sub.3-7cycloalkyl, pyrrolidinyl, piperidinyl, piperazinyl, 4-C.sub.1-6alkylpiperazinyl, 4-C.sub.1-6alkylcarbonylpiperazinyl, and morpholinyl; wherein the morpholinyl and piperidinyl groups may be optionally substituted with one or with two C.sub.1-6alkyl radicals; Het as a group or part of a group is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally condensed with a benzene ring; and wherein said Het as a whole is optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, hydroxy, nitro, cyano, carboxyl, C.sub.1-6alkyl, C.sub.1-6alkoxy, C.sub.1-6alkoxyC.sub.1-6alkyl, C.sub.1-6alkylcarbonyl, amino, mono- or di-C.sub.1-6alkylamino, azido, mercapto, polyhaloC.sub.1-6alkyl, polyhaloC.sub.1-6alkoxy, C.sub.3-7cycloalkyl, pyrrolidinyl, piperidinyl, piperazinyl, 4-C.sub.1-6alkylpiperazinyl, 4-C.sub.1-6alkylcarbonylpiperazinyl, and morpholinyl; wherein the morpholinyl and piperidinyl groups may be optionally substituted with one or with two C.sub.1-6alkyl radicals; and (b) another anti-HCV compound. 33. The pharmaceutical composition of claim 32 wherein the anti-HCV compund is an HCV polymerase inhibitor, an HCV protease inhibitor, an inhibitor of another target in the HCV life cycle, an immunomodulatory agent, an antiviral agent, or combinations thereof. 34. The pharmaceutical composition of claim 32 wherein the anti-HCV compound is an HCV polymerase inhibitor.